After three years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI 2017) last month in ...

New tuberculosis (TB) ethics guidance, launched today by the World Health Organization (WHO), aims to help ensure that countries implementing the End TB Strategy adhere to sound ethical standards to protect the rights of all those affected. TB, the world’s top infectious disease killer, claims 5 ...

On 6th March 2017, European AIDS Treatment Group and Treatment Action Group (TAG) have jointly organized the webinar on TB Diagnostics. Moderator: Evgenia Maron Speakers: Ruth McNerney, University of Cape Town – TB Diagnostics Erika Lessem, Treatment Action Group – Advocating for better TB diagnosis Presentations and documents of the webinar

Patients receiving long-term tenofovir therapy for hepatitis B virus (HBV) infection have an increased risk for abnormalities in bone metabolism, such as low serum phosphate, according to a study published in the Annals of Hepatology.1 Tenofovir, a first-line antiviral agent for HBV, is generally well-tolerated, although ...

The Stop TB Partnership delivered the letter to WHO requesting inclusion of Mycobacterium tuberculosis in the WHO’s Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. STOP TB PARTNERSHIP ANNOUNCEMENT Geneva, Switzerland – 6 March 2017 — We would like to ...

More research is needed into how the virus may affect cerebral small vessel disease, a leading cause of cognitive decline. Even when people with HIV are doing well on antiretroviral (ARV) treatment, they are apparently more likely to have certain abnormalities in blood vessels in the ...

The Advisory Committee on Immunization Practices voted today (February 22) in favor of a single-dose alternative to 3-dose revaccination for infants born to hepatitis B surface antigen-positive mothers who failed to respond to the initial hepatitis B vaccination series. In a 13-1 vote, with one recusal, ...

Close to 60% of adults benefiting from point-of-care CD4 cell count testing at HIV testing sites, accelerated antiretroviral (ART) initiation and SMS appointment reminders were retained in care after one year, compared to just 44% of those receiving the standard of care (SOC) in Mozambique, ...

SEATTLE — Integration of ART into maternal and child health services during the postnatal period leads to significant improvements in women’s participation in HIV care and resulting viral suppression, according to findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI). “To understand the context ...

Tuberculosis, the world’s leading infectious killer, may have finally met its match. Two new drug therapies may be able to cure all forms of tuberculosis – even the ones most difficult to treat. “We will have something to offer every single patient,” says Mel Spigelman, president ...

SEATTLE — Data from a study of HIV–infected infants who received early ART suggest the reservoir for HIV lies in cells that were infected before ART initiation. “This is important because we have to understand what the reservoir is to be able to target it and ...

Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a phase 2 clinical trial, according to study results presented on Tuesday at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle ...

Longer time living with diagnosed HIV infection is strongly associated with depression, anxiety and poor quality of life, according to UK research published in HIV Medicine. Older age in itself was not associated with symptoms of distress or poor mental health but did have an ...

Bioquark Inc. and SC21 Biotech are collaborating on novel cellular therapies for long term HIV control by cost effectively and industrially scaling the production of HIV resistant cells for allogeneic transplant needs. Phialdelphia, PA, February 11, 2017 – Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused ...

New Rochelle, NY, February 9, 2017—A comprehensive collection of articles describing the broad scope and current status of this global effort is published in a special issue of AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The third annual ...

Last June, a Perspective piece in the New England Journal of Medicine noted the critical place that the World Health Organization’s list of Essential Medicines had assumed in global health policy and responses — donors, governments and insurers were all more likely to invest in ...

Following individuals through the cascade of care, from HIV diagnosis to treatment and undetectable viral load, rather than taking snapshots of performance, has led researchers on a major South African study to pinpoint linkage to care after testing HIV positive as the biggest weakness of ...

A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the ...